Galectin Therapeutics Discusses Corporate Transformation, Progress Of NAVIGATE Trial And Outlines Strategy For Potential Phase 2 Cancer Immunotherapy Trial At Annual Meeting

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022
 

Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022
 

Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to advise on path forward in oncology

Cancer immunotherapy efforts likely to focus on Head and Neck cancers

Shareholders approved all proposals, including the reelection of its Board of Directors